A Maryland law crafted to deter companies from instituting large price increases on old, off-patent drugs was struck down by a federal appeals court Friday, in a decision that could give pause to other states considering similar legislation.
A Maryland law crafted to deter companies from instituting large price increases on old, off-patent drugs was struck down by a federal appeals court Friday, in a decision that could give pause to other states considering similar legislation.